Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Is Debiopharm Group late reporting EU clinical trials?
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine - Li - 2020 - Journal of the Chinese Chemical Society - Wiley Online Library
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
2020 Scientific Report
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
PDF) New clinical trial designs in the era of Precision Medicine
Phase 2 study of pembrolizumab in patients with advanced rare cancers | Journal for ImmunoTherapy of Cancer
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
